Real-world study: CyPass with phaco reduces IOP, medications
LOS ANGELES — Both number of medications and IOP remained reduced at 3 years in a European study of the Alcon CyPass micro-stent combined with cataract surgery, according to a speaker giving results of the CyCLE study.
The CyCLE was a registry study in the European Union designed to evaluate the long-term safety and surgical outcomes of the CyPass micro-stent in real-world clinical practice followed for 3 years.
“The 3-year safety profile of the supraciliary micro-stent gives long-term evidence of its compatibility with cataract surgery and the potential to implant the micro-stent earlier in the glaucoma treatment as compared with conventional filtration glaucoma surgery,” Magda Rau, MD, said at the American Society of Cataract and Refractive Surgery meeting.
Patients enrolled in the study were “all comers,” with refractory or non-refractory cases of primary or secondary open-angle glaucoma.
Of 245 eyes undergoing phacoemulsification combined with the CyPass, for the 93 eyes with uncontrolled baseline IOP of 21 mm Hg or higher, the therapeutic goal was to lower IOP. Of the remaining 152 eyes with controlled baseline IOP less than 21 mm Hg, the therapeutic goal was to reduce the number of medications.
In eyes with uncontrolled baseline IOP, the micro-stent reduced IOP from baseline by 28% to 34% through the 3-year follow-up period. Additionally, the proportion of eyes controlled with no medication increased from 8% at baseline to 19% at month 36.
In eyes with controlled baseline IOP, the micro-stent maintained IOP at constant levels and reduced the medication use from 2 to 1.1 through 3 years. Additionally, 45% of eyes used no medication at month 36 compared with 3% at baseline. – by Patricia Nale, ELS
Rau M. Results from the CyCLE study for supraciliary microstent implantation combined with cataract surgery for open-angle glaucoma. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 5-9, 2017; Los Angeles.
Disclosure: Rau reports no relevant financial disclosures.